Medivir splits R&D; BioMarin launches late-stage study of Pompe drug;

 @FierceBiotech: From FierceBiotechResearch.com: New database a boon for genomics research. Story | Follow @FierceBiotech

@JohnCFierce: Moderna will now triple its staff in Cambridge, MA, if you're looking for a job. Article | Follow @JohnCFierce

@RyanMFierce: Celgene makes big splash in gene therapy with two cancer collaborations. News | Follow @RyanMFierce

> Sweden's Medivir has decided to split its R&D operation into two groups--discovery research and development. The research organization will be helmed by Richard Bethell, who will assume the position as Executive Vice President Discovery Research on April 22. Release

> BioMarin Pharmaceutical ($BMRN) is moving forward with plans to launch a late-stage study of its experimental drug for Pompe disease. Story

> The U.K.'s cost-effectiveness watchdog has turned away Novartis' ($NVS) Afinitor for breast cancer. Story

Medical Device News

 @FierceMedDev: More worry for Intuitive as MA questions robotic surgery. Item | Follow @FierceMedDev

 @MarkHFierce: Our latest special report: Med Tech's 2012 R&D big spenders. Who made the list? Feature | Follow @MarkHFierce

 @DamianFierce: A House Dem has taken up the medical device tax repeal cause, introducing a bill to kill the charge. Report | Follow @DamianFierce

> St. Jude claims 'landmark study' quells concerns over heart plug benefits. Article

> Abbott's MitraClip draws mixed vote from FDA panel. News

> Swiss develop multitasking, implantable Dx chip. More

Pharma News

@FiercePharma: Novartis CEO Joe Jimenez's latest interview with a big media outlet. How $NVS forges ahead, from CNN. Report | Follow @FiercePharma

@EricPFierce: Canada's Apotex, already in NAFTA fight with US over 2009 FDA import ban, finds itself back in the FDA doghouse. Article | Follow @EricPFierce

> Novartis breast cancer drug Afinitor nixed by U.K. gatekeepers. Story

> Compounding pharmacy yanks sterile drugs after repacked Avastin triggered eye infections. News

> AstraZeneca to shed 2,300 jobs in sales, admin as it targets new growth. Report

Pharma Manufacturing News

> Teva returns to market with propofol. Story

> India has plan to meet Europe's new API regs. Report

> Sanofi again having manufacturing issues involving TB drug. Article

> FDA again on Apotex's case for plant problems. More

Vaccines News

> Flexible flu threatens pandemic preparedness. Report

> Anthrax vax vexes bioethics committee. Story

> U.K. smallpox rethink prompts stockpiling criticisms. Article

> Struggle against HPV vaccine skepticism intensifying. More

And Finally… A new study concludes that the last few meals you eat ahead of surgery could dictate the length of your recovery. Release

 

Suggested Articles

Targeting DUX4 might improve the success of immunotherapies, scientists at Fred Hutchinson Cancer Research Center suggest.

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.